Skip to main content

The MURDOCK Study: a long-term initiative for disease reclassification through advanced biomarker discovery and integration with electronic health records.

Publication ,  Journal Article
Tenenbaum, JD; Christian, V; Cornish, MA; Dolor, RJ; Dunham, AA; Ginsburg, GS; Kraus, VB; McHutchison, JG; Nahm, ML; Newby, LK; Svetkey, LP ...
Published in: Am J Transl Res
2012

BACKGROUND: Facing critically low return per dollar invested on clinical research and clinical care, the American biomedical enterprise is in need of a significant transformation. A confluence of high-throughput "omic" technologies and increasing adoption of the electronic health record has fueled excitement for a new paradigm for biomedical research and practice. The ability to simultaneously measure thousands of molecular variables and assess their relationships with clinical data collected during the course of care could enable reclassification of disease not only by gross phenotypic observation but according to underlying molecular mechanism and influence of social determinants.In turn, this reclassification could enable development of targeted therapeutic interventions as well as disease prevention strategies at the individual and population levels. METHODS/DESIGN: The MURDOCK Study consists of distinct project "horizons" or stages. Horizon 1 entailed the generation and analysis of molecular data for existing large,clinically well-annotated cohorts in four disease areas. Horizon 1.5 involves creating and maintaining a 50,000-person,community volunteer registry for biomarker signature validation and prospective studies, including integration of environmental and social data. Horizon 2 leverages and prospectively recruits Horizon 1.5 volunteers, and extends the study to additional disease areas of interest. Horizon 3 will expand the study through regional, national,and international partnerships. DISCUSSION: The MURDOCK Study embodies a new model of team science investigation and represents a significant resource for translational research. The study team invites inquiries to form new collaborations to exploit the rich resources provided by these biospecimens and associated study data.

Duke Scholars

Published In

Am J Transl Res

EISSN

1943-8141

Publication Date

2012

Volume

4

Issue

3

Start / End Page

291 / 301

Location

United States

Related Subject Headings

  • 3214 Pharmacology and pharmaceutical sciences
  • 3209 Neurosciences
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Tenenbaum, J. D., Christian, V., Cornish, M. A., Dolor, R. J., Dunham, A. A., Ginsburg, G. S., … Califf, R. M. (2012). The MURDOCK Study: a long-term initiative for disease reclassification through advanced biomarker discovery and integration with electronic health records. Am J Transl Res, 4(3), 291–301.
Tenenbaum, Jessica D., Victoria Christian, Melissa A. Cornish, Rowena J. Dolor, Ashley A. Dunham, Geoffrey S. Ginsburg, Virginia B. Kraus, et al. “The MURDOCK Study: a long-term initiative for disease reclassification through advanced biomarker discovery and integration with electronic health records.Am J Transl Res 4, no. 3 (2012): 291–301.
Tenenbaum JD, Christian V, Cornish MA, Dolor RJ, Dunham AA, Ginsburg GS, et al. The MURDOCK Study: a long-term initiative for disease reclassification through advanced biomarker discovery and integration with electronic health records. Am J Transl Res. 2012;4(3):291–301.
Tenenbaum JD, Christian V, Cornish MA, Dolor RJ, Dunham AA, Ginsburg GS, Kraus VB, McHutchison JG, Nahm ML, Newby LK, Svetkey LP, Udayakumar K, Califf RM. The MURDOCK Study: a long-term initiative for disease reclassification through advanced biomarker discovery and integration with electronic health records. Am J Transl Res. 2012;4(3):291–301.

Published In

Am J Transl Res

EISSN

1943-8141

Publication Date

2012

Volume

4

Issue

3

Start / End Page

291 / 301

Location

United States

Related Subject Headings

  • 3214 Pharmacology and pharmaceutical sciences
  • 3209 Neurosciences
  • 3202 Clinical sciences